FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942381680> ?p ?o ?g. }

• W2942381680 endingPage "81" @default.
• W2942381680 startingPage "75" @default.
• W2942381680 abstract "The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CLL patients with an intact TP53 gene and investigated four recurrently mutated genes in CLL, genomic aberrations by FISH, and IGHV status with the aim of analyzing their impact on progression-free survival (PFS) after front-line therapy with FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) regimens. Using next-generation sequencing, we analyzed 120 patients treated with FCR and 57 patients treated with BR at a university hospital. We used a 10% cut-off for variant allele frequency and recorded the following mutation frequencies in the pre-therapy samples: ATM 23%, SF3B1 20%, NOTCH1 19% and BIRC3 11%. The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. In univariate analyses, we observed a negative impact of BIRC3 mutations and 11q22 deletion in both regimens, while the unmutated IGHV status was associated with a significantly shorter PFS only in the FCR-treated cohort. In a multivariate analysis, only deletion 11q22 in both regimens, and the unmutated IGHV in the FCR cohort maintained an independent association with the reduced PFS. Notably, sole 11q22 deletion, without an ATM mutation on the other allele, manifested the shortest PFS of all analyzed markers. Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients." @default.
• W2942381680 created "2019-05-03" @default.
• W2942381680 creator A5008452187 @default.
• W2942381680 creator A5021107430 @default.
• W2942381680 creator A5024829432 @default.
• W2942381680 creator A5042672780 @default.
• W2942381680 creator A5046734583 @default.
• W2942381680 creator A5049999011 @default.
• W2942381680 creator A5054654885 @default.
• W2942381680 creator A5064699040 @default.
• W2942381680 creator A5065520471 @default.
• W2942381680 creator A5071015212 @default.
• W2942381680 creator A5078175773 @default.
• W2942381680 creator A5084649414 @default.
• W2942381680 date "2019-06-01" @default.
• W2942381680 modified "2023-10-18" @default.
• W2942381680 title "Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience" @default.
• W2942381680 cites W1196637763 @default.
• W2942381680 cites W1499230593 @default.
• W2942381680 cites W1971025765 @default.
• W2942381680 cites W1979960325 @default.
• W2942381680 cites W1983579522 @default.
• W2942381680 cites W1990089954 @default.
• W2942381680 cites W1999233413 @default.
• W2942381680 cites W2015592267 @default.
• W2942381680 cites W2016042196 @default.
• W2942381680 cites W2027246028 @default.
• W2942381680 cites W2046661227 @default.
• W2942381680 cites W2052346599 @default.
• W2942381680 cites W2078083587 @default.
• W2942381680 cites W2080959192 @default.
• W2942381680 cites W2082414447 @default.
• W2942381680 cites W2116431837 @default.
• W2942381680 cites W2120941289 @default.
• W2942381680 cites W2135604149 @default.
• W2942381680 cites W2136272158 @default.
• W2942381680 cites W2140606816 @default.
• W2942381680 cites W2144617723 @default.
• W2942381680 cites W2145842706 @default.
• W2942381680 cites W2162125647 @default.
• W2942381680 cites W2166117556 @default.
• W2942381680 cites W2222041965 @default.
• W2942381680 cites W2337485820 @default.
• W2942381680 cites W2343910676 @default.
• W2942381680 cites W2396328865 @default.
• W2942381680 cites W2755812911 @default.
• W2942381680 cites W2767685521 @default.
• W2942381680 cites W2790353541 @default.
• W2942381680 cites W2790385276 @default.
• W2942381680 cites W2791174505 @default.
• W2942381680 cites W2884311669 @default.
• W2942381680 cites W2902300122 @default.
• W2942381680 cites W2904301904 @default.
• W2942381680 cites W4212962560 @default.
• W2942381680 doi "https://doi.org/10.1016/j.leukres.2019.04.015" @default.
• W2942381680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31054420" @default.
• W2942381680 hasPublicationYear "2019" @default.
• W2942381680 type Work @default.
• W2942381680 sameAs 2942381680 @default.
• W2942381680 citedByCount "7" @default.
• W2942381680 countsByYear W29423816802020 @default.
• W2942381680 countsByYear W29423816802021 @default.
• W2942381680 countsByYear W29423816802022 @default.
• W2942381680 crossrefType "journal-article" @default.
• W2942381680 hasAuthorship W2942381680A5008452187 @default.
• W2942381680 hasAuthorship W2942381680A5021107430 @default.
• W2942381680 hasAuthorship W2942381680A5024829432 @default.
• W2942381680 hasAuthorship W2942381680A5042672780 @default.
• W2942381680 hasAuthorship W2942381680A5046734583 @default.
• W2942381680 hasAuthorship W2942381680A5049999011 @default.
• W2942381680 hasAuthorship W2942381680A5054654885 @default.
• W2942381680 hasAuthorship W2942381680A5064699040 @default.
• W2942381680 hasAuthorship W2942381680A5065520471 @default.
• W2942381680 hasAuthorship W2942381680A5071015212 @default.
• W2942381680 hasAuthorship W2942381680A5078175773 @default.
• W2942381680 hasAuthorship W2942381680A5084649414 @default.
• W2942381680 hasConcept C126322002 @default.
• W2942381680 hasConcept C143998085 @default.
• W2942381680 hasConcept C203014093 @default.
• W2942381680 hasConcept C2776694085 @default.
• W2942381680 hasConcept C2776755627 @default.
• W2942381680 hasConcept C2777609679 @default.
• W2942381680 hasConcept C2777938653 @default.
• W2942381680 hasConcept C2778461978 @default.
• W2942381680 hasConcept C2779263901 @default.
• W2942381680 hasConcept C2779338263 @default.
• W2942381680 hasConcept C2780653079 @default.
• W2942381680 hasConcept C2780739268 @default.
• W2942381680 hasConcept C2780790343 @default.
• W2942381680 hasConcept C2781442060 @default.
• W2942381680 hasConcept C502942594 @default.
• W2942381680 hasConcept C71924100 @default.
• W2942381680 hasConcept C86803240 @default.
• W2942381680 hasConceptScore W2942381680C126322002 @default.
• W2942381680 hasConceptScore W2942381680C143998085 @default.
• W2942381680 hasConceptScore W2942381680C203014093 @default.
• W2942381680 hasConceptScore W2942381680C2776694085 @default.
• W2942381680 hasConceptScore W2942381680C2776755627 @default.

• next